Vanguard Group’s Akcea Therapeutics Inc AKCA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2020
Q4 | – | Sell |
-1,372,903
| Closed | -$24.9M | – | 4258 |
|
|
2020
Q3 | $24.9M | Sell |
1,372,903
-91,232
| -6% | -$1.29M | ﹤0.01% | 2344 |
|
|
2020
Q2 | $20.1M | Buy |
1,464,135
+72,053
| +5% | +$1.11M | ﹤0.01% | 2430 |
|
|
2020
Q1 | $19.9M | Buy |
1,392,082
+37,800
| +3% | +$620K | ﹤0.01% | 2283 |
|
|
2019
Q4 | $22.9M | Sell |
1,354,282
-347,678
| -20% | -$6.47M | ﹤0.01% | 2466 |
|
|
2019
Q3 | $26.2M | Buy |
1,701,960
+99,984
| +6% | +$2.13M | ﹤0.01% | 2350 |
|
|
2019
Q2 | $37.6M | Buy |
1,601,976
+311,366
| +24% | +$7.69M | ﹤0.01% | 2247 |
|
|
2019
Q1 | $36.6M | Buy |
1,290,610
+47,537
| +4% | +$1.38M | ﹤0.01% | 2246 |
|
|
2018
Q4 | $37.5M | Buy |
1,243,073
+51,562
| +4% | +$1.45M | ﹤0.01% | 2157 |
|
|
2018
Q3 | $41.7M | Buy |
1,191,511
+31,714
| +3% | +$960K | ﹤0.01% | 2236 |
|
|
2018
Q2 | $27.5M | Buy |
1,159,797
+36,039
| +3% | +$860K | ﹤0.01% | 2424 |
|
|
2018
Q1 | $28.8M | Sell |
1,123,758
-56,337
| -5% | -$1.21M | ﹤0.01% | 2349 |
|
|
2017
Q4 | $20.5M | Buy |
1,180,095
+105,135
| +10% | +$2.06M | ﹤0.01% | 2476 |
|
|
2017
Q3 | $29.7M | Buy |
+1,074,960
| New | +$19.9M | ﹤0.01% | 2307 |
|
Vanguard Group's AKCA Position: Q4 2020 in Review
Vanguard Group sold out of Akcea Therapeutics Inc (AKCA) in Q4 2020, closing a stake of 1,372,903 shares — an estimated $24.9M sold.
Vanguard Group first reported a position in AKCA in Q3 2017 and held it in 13 quarters. The position peaked at $41.7M in Q3 2018. 0 funds tracked by Wall St. Rank hold AKCA as of Q4 2020.
- Vanguard Group reported no remaining Akcea Therapeutics Inc position as of Q4 2020 after selling out during the quarter.
- Vanguard Group sold 1,372,903 Akcea Therapeutics Inc shares in Q4 2020, an estimated $24.9M.
- Vanguard Group first reported a position in Akcea Therapeutics Inc in Q3 2017 and held it in 13 quarters.
- Vanguard Group's Akcea Therapeutics Inc position peaked at $41.7M in Q3 2018.
- 0 funds tracked by Wall St. Rank held Akcea Therapeutics Inc as of Q4 2020.
Based on Vanguard Group's 13F filing for Q4 2020, filed 12 Feb 2021.